iBio, Inc. Statistics
Total Valuation
iBio, Inc. has a market cap or net worth of $97.41 million. The enterprise value is $47.16 million.
Important Dates
The last earnings date was Tuesday, February 10, 2026, after market close.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
iBio, Inc. has 34.54 million shares outstanding. The number of shares has increased by 114.82% in one year.
| Current Share Class | 34.54M |
| Shares Outstanding | 34.54M |
| Shares Change (YoY) | +114.82% |
| Shares Change (QoQ) | +5.03% |
| Owned by Insiders (%) | 2.32% |
| Owned by Institutions (%) | 31.42% |
| Float | 27.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 324.71 |
| Forward PS | n/a |
| PB Ratio | 1.50 |
| P/TBV Ratio | 1.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 157.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.04, with a Debt / Equity ratio of 0.04.
| Current Ratio | 9.04 |
| Quick Ratio | 8.93 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -145.56 |
Financial Efficiency
Return on equity (ROE) is -70.22% and return on invested capital (ROIC) is -41.00%.
| Return on Equity (ROE) | -70.22% |
| Return on Assets (ROA) | -36.99% |
| Return on Invested Capital (ROIC) | -41.00% |
| Return on Capital Employed (ROCE) | -43.55% |
| Weighted Average Cost of Capital (WACC) | 10.99% |
| Revenue Per Employee | $15,000 |
| Profits Per Employee | -$1.24M |
| Employee Count | 20 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.00% in the last 52 weeks. The beta is 1.25, so iBio, Inc.'s price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | -25.00% |
| 50-Day Moving Average | 2.24 |
| 200-Day Moving Average | 1.27 |
| Relative Strength Index (RSI) | 62.55 |
| Average Volume (20 Days) | 1,217,766 |
Short Selling Information
The latest short interest is 4.18 million, so 12.11% of the outstanding shares have been sold short.
| Short Interest | 4.18M |
| Short Previous Month | 3.85M |
| Short % of Shares Out | 12.11% |
| Short % of Float | 15.46% |
| Short Ratio (days to cover) | 3.31 |
Income Statement
In the last 12 months, iBio, Inc. had revenue of $300,000 and -$24.74 million in losses. Loss per share was -$1.53.
| Revenue | 300,000 |
| Gross Profit | 300,000 |
| Operating Income | -25.47M |
| Pretax Income | -24.74M |
| Net Income | -24.74M |
| EBITDA | -24.74M |
| EBIT | -25.47M |
| Loss Per Share | -$1.53 |
Full Income StatementBalance Sheet
The company has $52.70 million in cash and $2.45 million in debt, with a net cash position of $50.25 million or $1.45 per share.
| Cash & Cash Equivalents | 52.70M |
| Total Debt | 2.45M |
| Net Cash | 50.25M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 56.56M |
| Book Value Per Share | 1.88 |
| Working Capital | 47.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.63 million and capital expenditures -$563,000, giving a free cash flow of -$19.19 million.
| Operating Cash Flow | -18.63M |
| Capital Expenditures | -563,000 |
| Free Cash Flow | -19.19M |
| FCF Per Share | -$0.56 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -8,491.00% |
| Pretax Margin | -8,245.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iBio, Inc. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -114.82% |
| Shareholder Yield | -114.82% |
| Earnings Yield | -25.39% |
| FCF Yield | -19.70% |
Analyst Forecast
The average price target for iBio, Inc. is $4.00, which is 41.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.00 |
| Price Target Difference | 41.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | -8.61% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 29, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Nov 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
iBio, Inc. has an Altman Z-Score of -6.14 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.14 |
| Piotroski F-Score | 2 |
